Fulcrum Therapeutics Q3 EPS $(0.39) Vs $(0.51) Last Year, Sales $759.00K Miss $1.05M Estimate
Portfolio Pulse from Benzinga Newsdesk
Fulcrum Therapeutics reported Q3 losses of $(0.39) per share, a 23.53% improvement from last year. However, the company's quarterly sales of $759.00K missed the analyst consensus estimate of $1.05M by 27.71%, marking a 35.84% decrease from the same period last year.
November 07, 2023 | 12:05 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Fulcrum Therapeutics reported improved Q3 EPS but missed sales estimates.
Fulcrum Therapeutics reported an improvement in its Q3 EPS, which is a positive sign. However, the company missed its sales estimates by a significant margin, which could negatively impact investor sentiment and potentially lead to a decrease in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100